Vaccine Sales Analysis 2016-2026

ワクチンの世界市場販売分析:小児用ワクチン、成人用ワクチン、高齢者用ワクチン、トラベルワクチン、治療ワクチン

◆タイトル:Vaccine Sales Analysis 2016-2026
◆商品コード:VGAIN6041535
◆調査・発行会社:visiongain
◆発行日:2016年3月
◆ページ数:186
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)GBP1,999 ⇒換算¥295,852見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"ワクチンの世界市場販売分析:小児用ワクチン、成人用ワクチン、高齢者用ワクチン、トラベルワクチン、治療ワクチン"について調査・分析し、レポートサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、研究開発パイプライン分析、結論などの情報をお届けいたします。

Vaccines – Your 2016 Guide to Developments, Opportunities and RevenuesWhat does the future hold for vaccine sales? Visiongain’s updated report shows you forecasted sales at overall world market, submarket, product and national level to 2026.

With that study you discover vaccine trends, R&D and revenue prospects for human healthcare. That way you can benefit your research, analysis, decisions and authority. For those technologies, assess sales potentials and opportunities.

Vaccines still hold great technological, medical and commercial potential. See why and what is possible. Read on, then, to explore that industry and see a revenue prediction.

Forecasts from 2016 to 2026 and other analyses showing you vaccine market potentials
Besides revenue forecasting to 2026, our new study gives you historical data, recent results, growth rates and market shares. There you find business outlooks and developments (R&D).

Our report gives you 52 tables and 56 charts. Gain analysis found nowhere else. Discover what the future holds for companies and the vaccines market.

Gains through exploring the vaccines industry – ways to benefit your plans and decisions
Leaders hold the latest knowledge – research and analysis. So explore, in our report, the development, production and sales of vaccines. There, from 2016, you see where needs and money exist for those preventative medicines. Discover what is possible.

Our study’s purpose is to help you avoid struggles to gain business data on vaccines. See how our predictions and discussions could benefit your reputation for commercial insight.

Discover, then, how you and your organisation can gain. The following sections show how our new investigation benefits your plans, decisions and presentations.

Revenues for the world vaccines market and submarkets – what is possible?
What is that industry’s potential? What are the secrets of its progress? Discover in our report overall world revenue forecasting to 2026. Also find individual predictions for four world level submarkets:
• Paediatric vaccines
• Adult vaccines
• Elderly vaccines
• Travel vaccines.

How will sales rise? And which product classes can generate most revenue? In our work you assess prospects for commercial expansion. You see which vaccine types hold greatest potential for sales growth and high revenues.

Benefit your knowledge and authority. You also discover sales potentials of vaccines by brand.

Forecasts and discussions for leading marketed products
How will leading brands perform from 2016 at world level? Our work shows you 10 individual revenue forecasts to 2026 for leading vaccines:
• Prevnar
• Gardasil
• Fluzone
• Pentacel
• ProQuad/M-M-R- II/Varivax.

You also see revenue predictions to 2026 for these products:
• Infanrix/Pediarix
• Zostavax
• RotaTeq
• GSK hepatitis franchise
• Menactra.

Avoid falling behind in information to help you stay competitive. Instead our work lets you assess potentials, seeing activities, results and outlooks. You discover what is happening, exploring trends, competition and sales prospects.

Our study also divides its overall world vaccines forecast into geographical regions.

Healthcare in national markets – what outlooks for sales of those medicines?
Progress worldwide in vaccines and healthcare from 2016 will increase vaccination. With our investigation you hear about the best revenue prospects for those medicines, assessing national prospects.

Our analysis shows you individual revenue forecasts to 2026 for 11 national markets:
• United States (US)
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5 countries)
• Brazil, Russia, India and China (BRIC group).

There you assess developed and developing countries for revenues and future sales growth. Our work explains. See effects of existing and future prophylactic medicines.

Future vaccines – assess emerging technologies, exploring research and development
Our study also shows you the most promising vaccines in development. There explore product candidates in these six classes:
• Prophylactic vaccines
• Products for children
• Agents for protecting adults
• Treatments for older people
• Travel vaccination
• Therapeutic vaccines.

R&D for vaccines holds great potential to benefit companies, healthcare providers and patients. See what technological, clinical and commercial opportunities exist, helping you stay ahead.

【レポートの目次】

1. Report Overview
1.1 Overview of the World Vaccines Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to the World Human Vaccines Market
2.1 Human Vaccines – Aiming for Global Disease Prevention
2.2 What is the Social and Economic Burden?
2.3 Vaccine Technology
2.3.1 Inactivated Vaccines
2.3.2 Live Attenuated Vaccines
2.3.3 Conjugate Vaccines
2.3.4 Recombinant Vector Vaccines
2.4 Key Influencers of the Human Vaccine Market
2.4.1 Governments and International Organizations
2.4.1.1 The World Health Organisation (WHO)
2.4.1.2 The Governmental Influence
2.4.2 Leading Manufacturers
2.4.2.1 Merck & Co.
2.4.2.2 Sanofi
2.4.2.3 GlaxoSmithKline
2.4.2.4 Pfizer
2.5 Human World Vaccines – Market Segmentation
2.5.1 Paediatric Vaccines
2.5.2 Adult Vaccines
2.5.3 Elderly Vaccines
2.5.4 Travel Vaccines
2.5.5 Therapeutic Vaccines

3. World Vaccine Market Outlook, 2016-2026
3.1 World Vaccine Market, 2015
3.1.1 Paediatric Vaccines Maintains Constant Demand
3.1.2 Ageing Population Requires More Care
3.1.3 Emerging Markets Demand Better Immunity
3.2 The World Human Vaccines Forecast, 2016-2026
3.3 The World Vaccine Market: Industry Trends, 2016-2026
3.3.1 Undulating Demand
3.3.2 Supply Restraints
3.3.3 Funding Trends
3.3.4 Protecting the Workforce of an Economy

4. World Vaccine Submarkets: Prospects, 2016-2026
4.1 Paediatric Vaccines
4.1.1 Paediatric Vaccine Forecast, 2016-2026
4.1.2 Paediatric Vaccine Trends
4.1.2.1 Innovative Delivery
4.1.2.2 Fear Factor
4.1.2.3 Novel Vectors
4.2 Adult Vaccines
4.2.1 Adult Vaccine Forecast, 2016-2026
4.2.2 Adult Vaccine Trends
4.2.2.1 Fighting the Flu
4.2.2.2 HPV
4.2.2.3 Repeat Doses for Continued Protection
4.3 Elderly Vaccines
4.3.1 Elderly Vaccine Forecast, 2016-2026
4.3.2 Elderly Vaccine Trends
4.3.2.1 With Age Comes Greater Risk
4.3.2.2 Ageing Population across the Globe
4.4 Travel Vaccines
4.4.1 Travel Vaccines Forecast, 2016-2026
4.4.2 Travel Vaccine Trends
4.4.2.1 Zika Virus Outbreak
4.4.2.2 Globalization Carries Diseases
4.5 Therapeutic Vaccines
4.5.1 Therapeutic Vaccine Trends

5. Leading Vaccines: Revenue Forecasts, 2016-2026
5.1 Prevnar – Pneumococcal Pneumonia
5.2 Gardasil – HPV
5.3 Fluzone – Influenza
5.4 Pentacel – DtaP, Polio, HiB
5.5 ProQuad / M-M-R II / Varivax – Varicella/Chickenpox, Measles, Mumps, Rubella.
5.6 Infanrix/Pediarix – Diptheria, Tetanus and Acellular Pertussis
5.7 Zostavax – Herpes
5.8 RotaTeq – Rotavirus
5.9 GSK Hepatitis Franchise – Hepatitis A & B
5.10 Menactra – Meningococcal

6. Leading Developed National Vaccines Markets, 2016-2026
6.1 The United States Vaccines Markets, 2016-2026
6.1.1 The US Vaccine Market, 2016
6.1.2 The US Vaccine Market Forecast, 2016-2026
6.2 Japanese Vaccines Market, 2016-2026
6.2.1 The Japanese Vaccine Market, 2016
6.2.2 The Japanese Vaccine Market Forecast, 2016-2026
6.2.3 Addressing the Alleged Vaccine Gap
6.3 EU5 Vaccine Market, 2016-2026
6.3.1 The EU5 Vaccine Market, 2016
6.3.2 The EU5 Vaccine Market Forecast, 2016-2026
6.4 United Kingdom Vaccine Market, 2016-2026
6.4.1 The UK Vaccine Market, 2016
6.4.2 The UK Vaccine Market Forecast, 2016-2026
6.5 France: Vaccine Market, 2016-2026
6.5.1 The French Vaccine Market, 2016
6.5.2 The French Vaccine Market Forecast, 2016-2026
6.5.3 French Healthcare System – Immunization Policy
6.6 Germany: Vaccine Market, 2016-2026
6.6.1 The German Vaccine Market, 2016
6.6.2 The German Vaccine Market Forecast, 2016-2026
6.7 Italy: Vaccine Market, 2016-2026
6.7.1 The Italian Vaccine Market, 2016
6.7.2 The Italian Vaccine Market Forecast, 2016-2026
6.7.3 Challenges in Public Healthcare
6.8 Spain: Vaccine Market 2016-2026
6.8.1 The Spanish Vaccine Market, 2016
6.8.2 The Spanish Vaccine Market Forecast, 2016-2026
6.8.3 District Rules – Economic Challenges

7. Leading Emerging National Markets, 2016-2026
7.1 China: Vaccine Market, 2016-2026
7.1.1 The Chinese Vaccine Market, 2016
7.1.2 The Chinese Vaccine Market Forecast, 2016-2026
7.1.3 Setting-Up Domestic Vaccine Industries
7.2 India: Vaccine Market, 2016-2026
7.2.1 The Indian Vaccine Market, 2016
7.2.2 The Indian Vaccine Market Forecast, 2016-2026
7.2.3 The Extent to which the Vaccine Market Can Flourish?
7.3 Brazil: Vaccine Market, 2016-2026
7.3.1 The Brazilian Vaccine Market, 2016
7.3.2 The Brazilian Vaccine Market Forecast, 2016-2026
7.3.3 Zika Outbreak
7.4 Russia: Vaccine Market, 2016-2026
7.4.1 The Russian Vaccine Market, 2016
7.4.2 The Russian Vaccine Market Forecast, 2016-2026
7.4.3 Power of the State

8. Leading Manufacturers of Vaccines for Human Use
8.1 GlaxoSmithKline (GSK)
8.1.1 GSK Vaccine Performance
8.1.2 GSK Developments
8.1.2.1 Mergers and Acquisitions
8.1.2.2 GSK Vaccine Pipeline
8.2 Merck & Co.
8.2.1 Merck Vaccine Performance
8.2.2 Merck Developments
8.2.2.1 Merck Market Movements
8.2.2.2 Collaborations
8.2.2.3 Merck Pipeline
8.3 Sanofi
8.3.1 Sanofi Vaccine Performance
8.3.2 Sanofi Developments
8.3.2.1 Mergers & Acquisitions
8.3.2.2 Sanofi Vaccine Pipeline
8.4 Pfizer
8.4.1 Pfizer Vaccine Performance
8.4.2 Pfizer Developments
8.4.2.1 Pfizer Mergers & Acquisitions
8.4.2.2 Pfizer Pipeline
8.5 Johnson & Johnson
8.6 AstraZeneca
8.7 Other Companies Serving the Vaccines Market

9. Research and Development, 2016
9.1 Prophylactic Vaccines R&D Pipeline
9.1.1 Paediatric Vaccines R&D Pipeline
9.1.2 Adult Vaccines R&D Pipeline
9.1.3 Elderly Vaccines R&D Pipeline
9.1.4 Travel Vaccines R&D Pipeline
9.2 Therapeutic Vaccines R&D Pipeline

10. Qualitative Analysis of the World Vaccines Market, 2016-2026
10.1 SWOT Analysis of the World Human Vaccines Market, 2016
10.1.1 Strengths
10.1.1.1 Ageing Population
10.1.1.2 Prevention is Better than Cure
10.1.1.3 Demand from Emerging Markets Continue
10.1.1.4 Promising R&D Pipeline
10.1.1.5 Increasing Awareness
10.1.2 Weaknesses
10.1.2.1 High Manufacturing Costs
10.1.2.2 Time Constraints
10.1.2.3 Barriers to Market Entry
10.1.3 Opportunities
10.1.3.1 Constant Improvements in Vaccine Technology and Delivery Methods
10.1.3.2 Shifting Focus on Adults Vaccines
10.1.4 Threats
10.1.4.1 Oligarchic Presence of Pharmaceutical Giants
10.1.4.2 Productivity Gap
10.2 STEP Analysis of the World Human Vaccines Industry and Market, 2016-2026
10.2.1 Social Factors
10.2.1.1 Maintaining a Healthier Workforce
10.2.1.2 Public Hesitation – Fear of Unwanted Side-Effects
10.2.2 Technological Forces
10.2.2.1 Evolution of Vaccine Technology Pave the Way for Prophylactics and Therapeutics
10.2.3 Economic Factors
10.2.3.1 High Costs of Production
10.2.3.2 Soaring Vaccines Demand from Developing Countries
10.2.4 Political Factors
10.2.4.1 Governments Play Crucial Roles in Vaccination

11. Conclusions
11.1 Segment Market Share Shift
11.2 Elderly People Become the New Target Market
11.3 Endemic Infections Drive Travel Vaccines Growth
11.4 Emerging Markets: High Demand for Vaccines
11.5 Demand in Mature Pharma Markets Continues: in Particular Japan Will Show Sales Growth
11.6 Strong and Diverse Research and Development
11.7 Concluding Remarks

List of Tables
Table 1.1 Selected National Vaccines Markets: Revenues ($bn) and Market Shares (%) by Leading Country, 2014, 2020 and 2026 (Sample)
Table 3.1 The Global Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGRs (%), 2015-2026
Table 4.1 World Vaccines Submarkets: Revenue Forecasts ($bn), 2015-2026
Table 4.2 World Vaccines Submarkets: Market Shares (%), 2015-2026
Table 4.3 World Paediatric Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.4 World Adult Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.5 World Elderly Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.6 World Travel Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.1 Prevnar Revenue ($bn), 2011-2014
Table 5.2 Prevnar Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.3 Gardasil Revenue ($bn), 2011-2014
Table 5.4 Gardasil Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.5 Fluzone/Vaxigrip: Revenue ($bn), 2012-2014
Table 5.6 Fluzone Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.7 Pentacel Revenue ($bn), 2012-2014
Table 5.8 Pentacel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.9 ProQuad / M-M-R II / Varivax Revenue ($bn), 2011-2014
Table 5.10 ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.11 Infanrix/Pediarix Revenue ($bn), 2012-2014
Table 5.12 Infanrix/Pediarix Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.13 Zostavax Revenue ($bn), 2011-2014
Table 5.14 Zostavax Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.15 RotaTeq Revenue ($bn), 2011-2014
Table 5.16 RotaTeq Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.17 GSK Hepatitis Franchise Revenue ($bn), 2012-2014
Table 5.18 GSK Hepatitis Franchise Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.19 Menactra Revenue ($bn), 2012-2014
Table 5.20 Menactra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.1 Leading National Market Revenue Forecasts ($bn), 2015, 2020, 2026
Table 6.2 Leading Developed National Market Revenue Forecasts ($bn), 2015, 2020, 2026
Table 6.3 Leading Developed National Market Shares (%), 2015, 2020, 2026
Table 6.4 The US Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.5 The Japanese Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.6 EU5 Vaccines World Market Shares (%), 2015, 2020, 2026
Table 6.7 EU5 Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.8 The UK Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.9 The French Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.10 The German Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.11 The Italian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.12 The Spanish Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.1 Leading Emerging National Market Revenue Forecasts ($bn), 2015, 2020, 2026
Table 7.2 Leading Emerging National Market Shares (%), 2015, 2020, 2026
Table 7.3 The Chinese Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.4 The Indian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.5 The Brazilian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.6 The Russian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 8.1 GSK Geographic Revenue ($bn), 2014
Table 9.1 Prophylactic Vaccines in Development, 2016
Table 9.2 Paediatric Vaccines in Development, 2016
Table 9.3 Adult Vaccines in Development, 2016
Table 9.4 Elderly Vaccines in Development, 2016
Table 9.5 Travel Vaccines in Development, 2016
Table 9.6 Therapeutic Vaccines in Development, 2016

List of Figures
Figure 1.1 World Vaccines Market Segmentation, 2016
Figure 3.1 Vaccines Market Share within Global Pharmaceutical Market (%), 2016
Figure 3.2 World Vaccines Leading National Market Shares (%), 2015
Figure 3.3 World Vaccines Leading National Market Shares (%), 2020
Figure 3.4 World Vaccines Leading National Market Shares (%), 2026
Figure 3.5 World Vaccines Market: Drivers and Restraints, 2016-2026
Figure 4.1 World Prophylactic Vaccines Submarket (%) Segmentation, 2015
Figure 4.2 World Paediatric Vaccines Market Share (%), 2014
Figure 4.3 World Paediatric Vaccines Market Share (%), 2020
Figure 4.4 World Paediatric Vaccines Market Share (%), 2026
Figure 4.5 World Paediatric Vaccines Revenue Forecast ($bn), 2015-2026
Figure 4.6 World Adult Vaccines Market Share (%), 2014
Figure 4.7 World Adult Vaccines Market Share (%), 2020
Figure 4.8 World Adult Vaccines Market Share (%), 2026
Figure 4.9 World Adult Vaccines Revenue Forecast ($bn), 2015-2026
Figure 4.10 World Elderly Vaccines Market Share (%), 2014
Figure 4.11 World Elderly Vaccines Market Share (%), 2020
Figure 4.12 World Elderly Vaccines Market Share (%), 2026
Figure 4.13 World Elderly Vaccines Revenue Forecast ($bn), 2015-2026
Figure 4.14 World Travel Vaccines Market Share (%), 2014
Figure 4.15 World Travel Vaccines Market Share (%), 2020
Figure 4.16 World Travel Vaccines Market Share (%), 2026
Figure 4.17 World Travel Vaccines Revenue Forecast ($bn), 2015-2026
Figure 5.1 Prevnar Revenue Forecast ($bn), 2015-2026
Figure 5.2 Gardasil Revenue Forecast ($bn), 2015-2026
Figure 5.3 Fluzone Revenue Forecast ($bn), 2015-2026
Figure 5.4 Pentacel Revenue Forecast ($bn), 2015-2026
Figure 5.5 ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), 2015-2026
Figure 5.6 Infanrix/Pediarix Revenue Forecast ($bn), 2015-2026
Figure 5.7 Zostavax Revenue Forecast ($bn), 2015-2026
Figure 5.8 RotaTeq Revenue Forecast ($bn), 2015-2026
Figure 5.9 GSK Hepatitis Franchise Revenue Forecast ($bn), 2015-2026
Figure 5.10 Menactra Revenue Forecast ($bn), 2015-2026
Figure 6.1 The US Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.2 The Japanese Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.3 EU5 Vaccines Market Share (%), 2015
Figure 6.4 EU5 Vaccines Market Share (%), 2020
Figure 6.5 EU5 Vaccines Market Share (%), 2026
Figure 6.6 The UK Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.7 The French Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.8 The German Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.9 The Italian Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.10 The Spanish Vaccines Revenue Forecast ($bn), 2015-2026
Figure 7.1 BRIC Countries Vaccines Market Share (%), 2015
Figure 7.2 BRIC Countries Vaccines Market Share (%), 2020
Figure 7.3 BRIC Countries Vaccines Market Share (%), 2026
Figure 7.4 The Chinese Vaccines Revenue Forecast ($bn), 2015-2026
Figure 7.5 The Indian Vaccines Revenue Forecast ($bn), 2015-2026
Figure 7.6 The Brazilian Vaccines Revenue Forecast ($bn), 2015-2026
Figure 7.7 The Russian Vaccines Revenue Forecast ($bn), 2015-2026
Figure 8.1 GSK Vaccines Revenue ($bn), 2012-2014
Figure 8.2 GSK Vaccines Region Breakdown (%), 2015
Figure 8.3 Merck Vaccines Revenue ($bn), 2011-2014
Figure 8.4 Sanofi Vaccines Revenue ($bn), 2012-2014
Figure 10.1 SWOT Analysis of the World Vaccines Market, 2016
Figure 10.2 STEP Analysis of the World Vaccines Market, 2016

【レポートのキーワード】

小児用ワクチン、成人用ワクチン、高齢者用ワクチン、トラベルワクチン、治療ワクチン、ワクチン販売

★調査レポート[ワクチンの世界市場販売分析:小児用ワクチン、成人用ワクチン、高齢者用ワクチン、トラベルワクチン、治療ワクチン] ( Vaccine Sales Analysis 2016-2026 / VGAIN6041535) 販売に関する免責事項
[ワクチンの世界市場販売分析:小児用ワクチン、成人用ワクチン、高齢者用ワクチン、トラベルワクチン、治療ワクチン] ( Vaccine Sales Analysis 2016-2026 / VGAIN6041535) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆